4//SEC Filing
Israel Biotech Fund I, L.P. 4
Accession 0000899243-20-013093
CIK 0001797336other
Filed
May 13, 8:00 PM ET
Accepted
May 14, 4:41 PM ET
Size
12.4 KB
Accession
0000899243-20-013093
Insider Transaction Report
Form 4
Israel Biotech Fund I, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-05-12+369,231→ 2,878,362 total - Conversion
Common Stock
2020-05-12+211,757→ 3,090,119 total - Purchase
Common Stock
2020-05-12$15.00/sh+225,000$3,375,000→ 3,315,119 total - Conversion
Series A Preferred Stock
2020-05-12−738,462→ 0 total→ Common Stock (369,231 underlying) - Conversion
Series B Preferred Stock
2020-05-12−423,514→ 0 total→ Common Stock (211,757 underlying)
Footnotes (1)
- [F1]Each share of preferred stock was automatically converted into 0.5 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date.
Documents
Issuer
Ayala Pharmaceuticals, Inc.
CIK 0001797336
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001652458
Filing Metadata
- Form type
- 4
- Filed
- May 13, 8:00 PM ET
- Accepted
- May 14, 4:41 PM ET
- Size
- 12.4 KB